Carebastine Almirall Prodesfarma
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://pubmed.ncbi.nlm.nih.gov/11249602
其他信息:
PMID: 11249602
作者: P Kingham; P Kingham; P Kingham
摘要: Carebastine, a histamine H1 antagonist, is under development by Almirall Prodesfarma for the potential treatment of allergic rhinitis, asthma and conjunctivitis. A nasal formulation was submitted for registration in Spain in June 1999 [343595]. It is also in phase III trials for conjunctivitis and phase I trials for asthma [343144,343243]. In a multicentered, multinational, double-blind, placebo-controlled study in patients with symptomatic SAR, patients were assigned a nasal spray formulation o...
